Public offerings often result in dilution of existing shares, which can lead to a decrease in stock price as the market adjusts to the increased number of shares available. The funds raised are intended for clinical development and corporate purposes, which may be positive in the long term, but the immediate impact is typically negative due to dilution concerns.